Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.83 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | DPP4 | P27487 | 1/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.74 |
| ▸ | RELA | Q04206 | 1/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.72 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.71 |
| ▸ | PARP1 | P09874 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.62 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.62 |
| ▸ | XDH | P47989 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834940 | 1.00 | TDP1 (0.83) | TDP1NFKB1DPP4NFKB2RELA | |
| Helichrysetin SCHEMBL30382622 | 0.93 | MAPT (0.82) | TDP1NFKB1DPP4NFKB2RELA | |
| Helichrysetin SCHEMBL2126372 | 0.93 | MAPT (0.82) | TDP1NFKB1DPP4NFKB2RELA | |
| Helichrysetin SCHEMBL2126376 | 0.93 | MAPT (0.82) | TDP1NFKB1DPP4NFKB2RELA | |
| Helichrysetin SCHEMBL30383770 | 0.91 | MAPT (0.80) | TDP1NFKB1DPP4NFKB2RELA | |
| SCHEMBL25200484 | 0.91 | NFKB1 (0.89) | TDP1NFKB1DPP4NFKB2RELA | |
| SCHEMBL633183 | 0.91 | NFKB1 (0.89) | TDP1NFKB1DPP4NFKB2RELA | |
| SCHEMBL4831543 | 0.91 | TDP1 (1.00) | TDP1NFKB1DPP4NFKB2RELA | |
| SCHEMBL633184 | 0.91 | NFKB1 (0.89) | TDP1NFKB1DPP4NFKB2RELA | |
| SCHEMBL4831536 | 0.91 | TDP1 (1.00) | TDP1NFKB1DPP4NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-107998113-A | Applications of the flavone compound CH625 in anti-glioma medicine is prepared | 武汉大学 | 2018-05-08 | — | — | CN | disclosed |
| US-7326734-B2 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-05 | — | — | US | disclosed |
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | TDP1 3071/4885NFKB1 1669/4885DPP4 4226/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | TDP1 3151/4885NFKB1 2437/4885DPP4 3670/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | TDP1 3151/4885NFKB1 2437/4885DPP4 3670/4885 |
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | KLK5, KLK4, KLK6 | TDP1 2857/4885NFKB1 2579/4885DPP4 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.